{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:06:02Z","timestamp":1790690762292,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF-PPS2023-15556"],"award-info":[{"award-number":["KWF-PPS2023-15556"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021217","name":"Central Agricultural University, Imphal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022721","name":"Stichting Villa Joep","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KFO 5010\/1"],"award-info":[{"award-number":["KFO 5010\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG INST 186\/1465-1"],"award-info":[{"award-number":["DFG INST 186\/1465-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100242","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:18:50Z","timestamp":1778019530000},"page":"100242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myeloid cell\u2013mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47\/SIRP\u03b1 interference"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9368-5661","authenticated-orcid":false,"given":"Marta","family":"Lustig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Kowol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0638-0000","authenticated-orcid":false,"given":"Alina M.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1959-2344","authenticated-orcid":false,"given":"Ida C.","family":"van der Peet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco J.H.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Iben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9840-8074","authenticated-orcid":false,"given":"Dorothee","family":"Winterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Krohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thies","family":"R\u00f6sner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Bendig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Wurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina L.","family":"Gehlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Denker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7991-6414","authenticated-orcid":false,"given":"Pipob","family":"Suwanchaikasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Macarr\u00f3n Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-5793","authenticated-orcid":false,"given":"Stefan","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5626-4967","authenticated-orcid":false,"given":"Katja","family":"Klausz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Valerius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-5332","authenticated-orcid":false,"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-9437","authenticated-orcid":false,"given":"Lorenz","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia D.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Peipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4982-6914","authenticated-orcid":false,"given":"Jeanette H.W.","family":"Leusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis M.","family":"Schewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9181-8067","authenticated-orcid":false,"given":"Thomas","family":"Valerius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.bneo.2026.100242_bib1","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100242_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"14","key":"10.1016\/j.bneo.2026.100242_bib3","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1182\/blood.2023022921","article-title":"Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia","volume":"145","author":"Badar","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100242_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.bneo.2026.100242_bib5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard risk pediatric B-acute lymphoblastic leukemia","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bneo.2026.100242_bib6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bneo.2026.100242_bib7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bneo.2026.100242_bib8","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.bneo.2026.100242_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","article-title":"Functional states of myeloid cells in cancer","volume":"41","author":"van Vlerken-Ysla","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bneo.2026.100242_bib10","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ccell.2020.04.015","article-title":"Extensive remodeling of the immune microenvironment in B cell acute lymphoblastic leukemia","volume":"37","author":"Witkowski","year":"2020","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.bneo.2026.100242_bib11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.bneo.2026.100242_bib12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/imr.13265","article-title":"Antibody-mediated phagocytosis in cancer immunotherapy","volume":"319","author":"Van Wagoner","year":"2023","journal-title":"Immunol Rev"},{"issue":"12","key":"10.1016\/j.bneo.2026.100242_bib13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor\u2013dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.bneo.2026.100242_bib14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2008-01-135160","article-title":"Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc\u03b3RI, Fc\u03b3RIII, and Fc\u03b3RIV","volume":"112","author":"Minard-Colin","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100242_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/srep34382","article-title":"Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies","volume":"6","author":"Grandjean","year":"2016","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.bneo.2026.100242_bib16","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.bneo.2026.100242_bib17","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"10.1016\/j.bneo.2026.100242_bib18","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1182\/blood-2017-01-764316","article-title":"An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts","volume":"130","author":"Schewe","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2026.100242_bib19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4161\/mabs.27457","article-title":"Increasing Fc\u03b3RIIa affinity of an Fc\u03b3RIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity","volume":"6","author":"Derer","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.bneo.2026.100242_bib20","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.3389\/fimmu.2018.03124","article-title":"Fc\u03b3RIIIb restricts antibody-dependent destruction of cancer cells by human neutrophils","volume":"9","author":"Treffers","year":"2019","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100242_bib21","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/emmm.201201929","article-title":"IgA EGFR antibodies mediate tumour killing in vivo","volume":"5","author":"Boross","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1016\/j.bneo.2026.100242_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/0008-5472.CAN-15-1232","article-title":"An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement in vivo","volume":"76","author":"Lohse","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.bneo.2026.100242_bib23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3389\/fimmu.2019.00704","article-title":"Potent Fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG","volume":"10","author":"Brandsma","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100242_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/2326-6066.CIR-19-0144","article-title":"IgA-mediated killing of tumor cells by neutrophils is enhanced by CD47-SIRP\u03b1 checkpoint inhibition","volume":"8","author":"Treffers","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"10.1016\/j.bneo.2026.100242_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008478","article-title":"Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockade","volume":"12","author":"Chan","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.bneo.2026.100242_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bneo.2026.100242_bib27","article-title":"CD47\u2013SIRP\u03b1-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immunooncol Technol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100242_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood.2021014485","article-title":"Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL","volume":"140","author":"M\u00fcller","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2026.100242_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.48","article-title":"Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade","volume":"8","author":"Schewe","year":"2024","journal-title":"Hemasphere"},{"issue":"18","key":"10.1016\/j.bneo.2026.100242_bib30","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2026.100242_bib31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100242_bib32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41590-022-01153-x","article-title":"Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunity","volume":"23","author":"Barreira da Silva","year":"2022","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100242_bib33","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41591-019-0356-z","article-title":"Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRP\u03b1 axis and a target for cancer immunotherapy","volume":"25","author":"Logtenberg","year":"2019","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.bneo.2026.100242_bib34","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41422-019-0177-0","article-title":"Identification of glutaminyl cyclase isoenzyme isoQC as a regulator of SIRP\u03b1-CD47 axis","volume":"29","author":"Wu","year":"2019","journal-title":"Cell Res"},{"issue":"8","key":"10.1016\/j.bneo.2026.100242_bib35","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1111\/cas.14999","article-title":"Enhancement of EGFR antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47\/SIRP\u03b1 interactions","volume":"112","author":"Baumann","year":"2021","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.bneo.2026.100242_bib36","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000939","article-title":"The gene expression classifier ALLCatchR identifies B-cell precursor ALL subtypes and underlying developmental trajectories across age","volume":"7","author":"Beder","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.bneo.2026.100242_bib37","author":"Kolde"},{"key":"10.1016\/j.bneo.2026.100242_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.949140","article-title":"Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab","volume":"13","author":"Baumann","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.bneo.2026.100242_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.957874","article-title":"Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody","volume":"13","author":"Gehlert","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100242_bib40","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1007\/s00262-023-03478-4","article-title":"Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains","volume":"72","author":"Stip","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bneo.2026.100242_bib41","author":"Kassambara"},{"issue":"10","key":"10.1016\/j.bneo.2026.100242_bib42","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bneo.2026.100242_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0952-7915(93)90006-E","article-title":"Generation and regeneration of cells of the B-lymphocyte lineage","volume":"5","author":"Rolink","year":"1993","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100242_bib44","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bneo.2026.100242_bib45","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1182\/blood.2023022919","article-title":"Genetic subtypes of B-cell acute lymphoblastic leukemia in adults","volume":"145","author":"Passet","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2026.100242_bib46","doi-asserted-by":"crossref","DOI":"10.4161\/onci.24052","article-title":"EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies","volume":"2","author":"Derer","year":"2013","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.bneo.2026.100242_bib47","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.4049\/jimmunol.1601473","article-title":"Antibody distance from the cell membrane regulates antibody effector mechanisms","volume":"198","author":"Cleary","year":"2017","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100242_bib48","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/0008-5472.CAN-23-2135","article-title":"Human tumor\u2013associated macrophages and neutrophils regulate antitumor antibody efficacy through lethal and sublethal trogocytosis","volume":"84","author":"Singhal","year":"2024","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.bneo.2026.100242_bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41571-018-0155-3","article-title":"Myeloid immune-checkpoint inhibition enters the clinical stage","volume":"16","author":"van den Berg","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100242_bib50","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41551-023-01088-0","article-title":"Phagocytic cooperativity by tumour macrophages","volume":"7","author":"Maoz","year":"2023","journal-title":"Nat Biomed Eng"},{"issue":"19","key":"10.1016\/j.bneo.2026.100242_bib51","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1182\/bloodadvances.2021004598","article-title":"The selection of variable regions affects effector mechanisms of IgA antibodies against CD20","volume":"5","author":"Evers","year":"2021","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.bneo.2026.100242_bib52","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood.2024026118","article-title":"Dar-ting at CD38 in T-cell leukemias","volume":"144","author":"Senapati","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2026.100242_bib53","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.4049\/jimmunol.165.10.5954","article-title":"Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy","volume":"165","author":"Stockmeyer","year":"2000","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100242_bib54","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.molcel.2008.05.026","article-title":"Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47","volume":"31","author":"Hatherley","year":"2008","journal-title":"Mol Cell"},{"issue":"37","key":"10.1016\/j.bneo.2026.100242_bib55","doi-asserted-by":"crossref","first-page":"13117","DOI":"10.1073\/pnas.0504184102","article-title":"Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation","volume":"102","author":"Huang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.bneo.2026.100242_bib56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/antib6030012","article-title":"Functional, biophysical, and structural characterization of human IgG1 and IgG4 Fc variants with ablated immune functionality","volume":"6","author":"Tam","year":"2017","journal-title":"Antibodies"},{"issue":"2","key":"10.1016\/j.bneo.2026.100242_bib57","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1021\/acs.jmedchem.4c02247","article-title":"Targeting QPCTL: an emerging therapeutic opportunity","volume":"68","author":"Yu","year":"2025","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bneo.2026.100242_bib58","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2026.100242_bib59","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med Overseas Ed"},{"key":"10.1016\/j.bneo.2026.100242_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104317","article-title":"Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults","volume":"196","author":"Kegyes","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"14","key":"10.1016\/j.bneo.2026.100242_bib61","first-page":"3051","article-title":"Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells","volume":"58","author":"W\u00fcrflein","year":"1998","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.bneo.2026.100242_bib62","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.4049\/jimmunol.168.7.3275","article-title":"Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity","volume":"168","author":"Tiroch","year":"2002","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100242_bib63","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.bneo.2026.100242_bib64","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41577-024-01038-0","article-title":"FAS signalling pathway is crucial for CAR T cell persistence","volume":"24","author":"Loves","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100242_bib65","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41467-021-21445-4","article-title":"Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation","volume":"12","author":"Arenas","year":"2021","journal-title":"Nat Commun"},{"issue":"7877","key":"10.1016\/j.bneo.2026.100242_bib66","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-021-03879-4","article-title":"Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis","volume":"597","author":"Kamber","year":"2021","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.bneo.2026.100242_bib67","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.celrep.2018.05.082","article-title":"Neutrophils kill antibody-opsonized cancer cells by trogoptosis","volume":"23","author":"Matlung","year":"2018","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.bneo.2026.100242_bib68","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.bneo.2026.100242_bib69","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231222","article-title":"Five decades of natural killer cell discovery","volume":"221","author":"Lanier","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.bneo.2026.100242_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1344761","article-title":"SKAP2 acts downstream of CD11b\/CD18 and regulates neutrophil effector function","volume":"15","author":"Bouti","year":"2024","journal-title":"Front Immunol"},{"issue":"18","key":"10.1016\/j.bneo.2026.100242_bib71","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1056\/NEJMe2504273","article-title":"Targeting the tumor and the immune system in smoldering multiple myeloma","volume":"392","author":"Maura","year":"2025","journal-title":"N Engl J Med Overseas Ed"},{"issue":"21","key":"10.1016\/j.bneo.2026.100242_bib72","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.2024024493","article-title":"Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study","volume":"144","author":"Bhatla","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2026.100242_bib73","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47\u2013SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100242_bib74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"Biomark Res"},{"key":"10.1016\/j.bneo.2026.100242_bib75","article-title":"Unbiased discovery of antibody therapies that stimulate macrophage-mediated destruction of B-cell lymphoma","author":"Ribeiro","year":"2024","journal-title":"bioRxiv"},{"issue":"S2","key":"10.1016\/j.bneo.2026.100242_bib76","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hon.3164_434","article-title":"First-in-human (FIH) study of the fully-human kappa-lambda CD19\/CD47 bispecific antibody TG-1801 in patients with B-cell lymphoma","volume":"41","author":"Hawkes","year":"2023","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100242_bib77","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1038\/s41467-024-46310-y","article-title":"Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma","volume":"15","author":"Grandcl\u00e9ment","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.bneo.2026.100242_bib78","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/antib9040070","article-title":"Fc engineering strategies to advance IgA antibodies as therapeutic agents","volume":"9","author":"van Tetering","year":"2020","journal-title":"Antibodies"},{"issue":"D1","key":"10.1016\/j.bneo.2026.100242_bib79","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","article-title":"The PRIDE database at 20 years: 2025 update","volume":"53","author":"Perez-Riverol","year":"2025","journal-title":"Nucleic Acids Res"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:17:09Z","timestamp":1790687829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000531"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100242","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid cell\u2013mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47\/SIRP\u03b1 interference","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100242"}}